Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: A randomised controlled trial

Thorax

Volumn 70, Issue 10, 2015, Pages 930-938

  Brill, Simon E ^a   Law, Martin ^b   El Emir, Ethaar ^a   Allinson, James P ^a   James, Phillip ^a   Maddox, Victoria ^c   Donaldson, Gavin C ^a   McHugh, Timothy D ^c   Cookson, William O ^a   Moffatt, Miriam F ^a   Nazareth, Irwin ^c   Hurst, John R ^c   Calverley, Peter M A ^d   Sweeting, Michael J ^e   Wedzicha, Jadwiga A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MOXIFLOXACIN; PLACEBO; RNA 16S; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; COMPLICATION; MICROBIOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; RESPIRATORY SYSTEM; SINGLE BLIND PROCEDURE; SPUTUM;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL LOAD; DOXYCYCLINE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SINGLE-BLIND METHOD; SPUTUM;

EID: 84942087062     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207194     Document Type: Article

References (33)

1. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(5 Pt 1):1418-22.
2. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
3. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
4. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96.
5. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
6. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
7. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
8. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-64.
9. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47.
10. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
11. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
12. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.
13. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1:262-74.
14. Cox MJ, Cookson WO, Moffatt MF. Sequencing the human microbiome in health and disease. Hum Mol Genet 2013;22(R1):R88-94.
15. Miller MR, Hankinson J, Brusasco V, et al Standardisation of spirometry. Eur Respir J 2005;26:319-38.
16. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
17. Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol 1995;48:719-24.
18. George SN, Garcha DS, Mackay AJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J 2014;44:87-96.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
20. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1224-31.
21. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;67:1075-80.
22. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:356-61.
23. Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 2014; 52:2813-23.
24. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012;336:489-93.
25. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8.
26. Siva R, Bafadhel M, Monteiro W, et al. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis 2014;9:179-86.
27. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
28. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90.
29. Dalhoff A. Resistance surveillance studies: a multifaceted problem - the fluoroquinolone example. Infection 2012;40:239-62.
30. Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Cell Physiol 2010;299:C539-48.
31. Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect 2012;14:573-83.
32. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. Brit Med J 2013;346:f1235.
33. Wenzel RP, Fowler AA III, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012;367:340-7.